Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

25.59 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Deciphera Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million. 
Via Benzinga
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Raises $150M Via Equity Offering
Via Benzinga
Deciphera Pharmaceuticals Inc. (DCPH) Climbs to Annual-High Share Price
Via Investor Brand Network
Short Volatility Alert: Deciphera Pharmaceuticals, Inc.
On Friday, shares of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) experienced volatile short activity. After the activity, the stock price moved down -5.45% to $11.27. The overall sentiment for DCPH... 
Via Benzinga
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Inc. (DCPH) Climbs to Annual-High Share Price
Via Investor Brand Network
Preview: Deciphera Pharmaceuticals's Earnings
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Deciphera Pharmaceuticals Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET
Deciphera Pharmaceuticals (NASDAQ:DCPH) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:... 
Via Benzinga
Deciphera's DCC-3116/KRAS Inhibitor Combo Shows Deeper, Longer Tumor Regressions In Preclinical Studies
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)  
Via Benzinga
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Deciphera Pharmaceuticals Inc. Climbs To Annual-High Share Price
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared... 
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For February 8, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.